ARTICLE | Clinical News
Tivantinib: Phase II data
November 24, 2014 8:00 AM UTC
Top-line data from an NIH-sponsored, double-blind, U.S. Phase II trial in 78 chemotherapy-naïve patients with asymptomatic or minimally symptomatic metastatic CRPC showed that twice-daily 360 mg oral ...